Drug Profile
Research programme: peptide therapeutics - Blueberry Therapeutics
Alternative Names: BB 0109; BB 2702; BB 5000Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Blueberry Therapeutics
- Class
- Mechanism of Action Bacterial growth inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atopic dermatitis; Bacterial infections; Inflammatory bowel diseases
Most Recent Events
- 25 Aug 2023 Preclinical development is ongoing for Inflammatory bowel disease, Atopic dermatitis and bacterial infections in United Kingdom (Blueberry therapeutics website, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Atopic-dermatitis in United Kingdom
- 28 Feb 2020 No recent reports of development identified for preclinical development in Bacterial-infections in United Kingdom